News | May 10, 2023
Boehringer Ingelheim begins clinical development for fibrotic diseases
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
Research collaboration covers multiple antibody research programs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)